Computational prediction of drug-target interactions (DTIs) and drug repositioning provides a low-cost and high-efficiency approach for drug discovery and development. The traditional social network-derived methods based on the naïve DTI topology information cannot predict potential targets for new chemical entities or failed drugs in clinical trials. There are currently millions of commercially available molecules with biologically relevant representations in chemical databases. It is urgent to develop novel computational approaches to predict targets for new chemical entities and failed drugs on a large scale. In this study, we developed a useful tool, namely substructure-drug-target network-based inference (SDTNBI), to prioritize potential targets for old drugs, failed drugs and new chemical entities. SDTNBI incorporates network and chemoinformatics to bridge the gap between new chemical entities and known DTI network. High performance was yielded in 10-fold and leave-one-out cross validations using four benchmark data sets, covering G protein-coupled receptors, kinases, ion channels and nuclear receptors. Furthermore, the highest areas under the receiver operating characteristic curve were 0.797 and 0.863 for two external validation sets, respectively. Finally, we identified thousands of new potential DTIs via implementing SDTNBI on a global network. As a proof-of-principle, we showcased the use of SDTNBI to identify novel anticancer indications for nonsteroidal anti-inflammatory drugs by inhibiting AKR1C3, CA9 or CA12. In summary, SDTNBI is a powerful network-based approach that predicts potential targets for new chemical entities on a large scale and will provide a new tool for DTI prediction and drug repositioning. The program and predicted DTIs are available on request.
Introduction
Over the past decades, traditional drug discovery paradigm has achieved a measure of success. But since the new century, this paradigm based on the hypothesis of 'one gene, one drug, one disease' has been facing many tricky challenges, such as high clinical attrition rate [1, 2] . Because of the rapid development of systems biology, a new paradigm named network pharmacology has put forward some fresh ideas and concepts to solve the aforementioned challenges [2] . Under this novel perspective, a single drug might act on multiple targets. Hence, drugs and targets can be organized as a complex network through numerous drug-target interactions (DTIs). Identification of new DTIs will help investigators to understand the therapeutic profiles or side effects of drugs, and find new uses for old drugs, namely drug repositioning [3] [4] [5] [6] . However, to identify potential DTIs with low cost and high efficiency is still a big challenge. Therefore, it is urgently needed to develop novel approaches for DTI prediction and drug repositioning during drug discovery and development.
Comparing with traditional experimental assays, computational approaches have made it possible for us to quickly and inexpensively identify potential DTIs and repurpose existing drugs [6, 7] . These approaches include molecular docking [8, 9] , machine learning [10] [11] [12] , similarity-based methods [13, 14] , etc. In recent years, another important series of computational approaches, namely network-based methods, was proposed for DTI prediction and drug repositioning. For instance, our group presented three network-based methods derived from recommendation algorithms for social networks, including networkbased inference (NBI), drug-based similarity inference and target-based similarity inference. Several newly predicted interactions via NBI for five old drugs on estrogen receptors or dipeptidyl peptidase IV were validated by in vitro assays [15] . Furthermore, we improved the NBI method by assigning weighted values to edges or nodes, namely edge-weighted NBI (EWNBI) and node-weighted NBI (NWNBI), respectively [16] . The systematic evaluation revealed that the two weighted NBI methods marginally outperform the original NBI. Alaimo et al. [17] introduced a network-based method called domain tunedhybrid (DT-Hybrid) derived from the NBI method. High performance was yielded for the DT-Hybrid by considering the additional knowledge about drug similarity and target similarity. Chen et al. [18] reported a method of Network-based Random Walk with Restart on the Heterogeneous network (NRWRH), which was an improvement of the random walk method by integrating three types of networks.
Despite their successful applications in DTI prediction and drug repositioning for known drugs, the aforementioned methods have an enormous limitation in the application domain: they cannot be used to predict potential targets for new chemical entities. These traditional network-based methods only used the naïve topology information in the existing DTI network [16] [17] [18] . Thus, they cannot interlink known DTI network with molecules without known target, such as new synthesized chemical structures and drugs failed in clinical trials. However, there are currently over 68 million commercially available molecules, including a large portion of described natural products in the ZINC database [19] . In addition, thousands of drugs with good pharmacokinetic properties and low toxicity are failed in clinical phases II and III because of poor clinical utility on the specific targets [20, 21] . The US National Center for Advancing Translational Sciences is spending US$20 million to focus initially on repurposing 58 failed drugs [22] . Therefore, it becomes urgent and important to develop novel computational approaches, such as network-based approaches, to predict potential targets for new chemical entities and failed drugs on a large scale.
In this study, we proposed an integrated network and chemoinformatics tool, named substructure-drug-target networkbased inference (SDTNBI), for large-scale DTI prediction and drug repositioning. SDTNBI uses the chemical substructure, which is a defined series of features that can be shared by chemical structures, to bridge the gap between known drugs and new chemical entities. Previous studies have suggested that chemical substructures play crucial roles for computational evaluation of drug pharmacokinetics and DTI prediction [10, [23] [24] [25] . Specifically, SDTNBI integrates known DTI network, drugsubstructure linkages and new chemical entity-substructure linkages to infer new targets for old drugs, failed drugs and new chemical entities in a way of resource diffusion ( Figure 1 ). Systematic evaluation based on 10-fold cross validation, leaveone-out cross validation and external validation showed high accuracy and robustness of SDTNBI. Furthermore, we built a global network and computationally identified thousands of new potential DTIs via SDTNBI. As a proof-of-principle, we showcased the use of SDTNBI to identify novel anticancer indications for nonsteroidal anti-inflammatory drugs (NSAIDs) by inhibiting AKR1C3, CA9, CA12 or CDK2. Put together, SDTNBI will provide a new alternative tool for DTI prediction and drug repositioning on a large scale during drug discovery and development.
Materials and methods

Data sets
Two DTI networks containing known chemical-protein interactions for G protein-coupled receptors (GPCRs) and kinase superfamily (Kinases) were collected from the ChEMBL database (accessed in May 2010) [26] . Two external validation sets corresponding to the two DTI networks were collected from the DrugBank database [27] . These DTI networks and external validation sets of GPCRs and Kinases were prepared based on our previous study [16] . In addition, we further compiled two DTI networks covering ion channels (ICs) and nuclear receptors (NRs) to cover more target families by integrating bioactivity data from the ChEMBL database (version 19) [26] and BindingDB database (downloaded in 2014) [28] . Chemical structures were converted into canonical SMILES format. Five physicochemical properties: molecular weight (MW), log P, the number of hydrogen bond donors (HBDs) and the number of hydrogen bond acceptors (HBAs), were calculated by using the OpenBabel toolkit (version 2.3.2) [29] . Only those data items that met the following five criteria were retained: (i) K i , K d , IC 50 or EC 50 10 mM; (ii) the target is a human protein; (iii) the target can be represented in a unique UniProt accession number; (iv) the compound can be successfully represented in canonical SMILES format; (v) the compound is drug-like, namely MW 500 Dalton, log P 5, the number of HBDs 5 and the number of HBAs 10. Finally, two DTI networks of ICs and NRs were built by removing duplicates from different data sources.
Furthermore, in order to construct a global network covering genome-wide targets, a comprehensive DTI network was built. All drugs in this data set were downloaded from the DrugBank database (version 4.1) [27] . Only those molecules whose structure was explicitly given were used. Molecules with conflicting structures were removed. Bioactivity data of these selected drugs were extracted from the aforementioned prepared databases using the same filtering criteria, except drug-like properties.
Chemical substructure dictionary
In this study, we systematically evaluated the performance of seven types of fingerprints generated by the PaDEL-Descriptor software (version 2.18) [30] , including CDK Fingerprint (CDK), CDK Extended Fingerprint (CDKExt), CDK Graph Only Fingerprint (Graph), MACCS Fingerprint (MACCS), PubChem Fingerprint (PubChem), Substructure Fingerprint (FP4) and Klekota-Roth Fingerprint (KR). These fingerprints were used to represent chemical substructures for each molecule. In addition, salt ions were removed from molecules, and nitro groups were standardized in this step.
Description of SDTNBI
Network construction
As described in Figure 1A , known DTI bipartite networks and drug-substructure linkages were obtained after data preparation and chemical substructure generation. They were subsequently integrated to construct a substructure-drug-target network. Denoting that D ¼ fD 1 ; D 2 ; . . . ; D ND g is a set of N D known drugs, S ¼ fS 1 ; S 2 ; . . . ; S NS g is a set of N S chemical substructures and T ¼ fT 1 ; T 2 ; . . . ; T NT g is a set of N T targets. The substructure-drug-target network can be represented as a tripartite graph G(V, E), where V ¼ D [ S [ T is the set of its vertices, and E is the set of its edges containing DTIs and drugsubstructure linkages.
Such substructure-drug-target network can be used to prioritize potential DTIs for known drugs appearing in the existing network via calculation processes explained in next subsection, but not enough for target prediction of new chemical entities.
To solve this issue, we built linkages between the new chemical entities and the known substructure-drug-target network through substructures shared by the new chemical entities and known drugs in the existing DTI network. Let C ¼ fC 1 ; C 2 ; . . . ; C NC g be a set of N C new chemical entities. This substructure-drug (and new chemical entity)-target network, which is an extension of graph G, can be represented as a new graph Figure 1B showed an example of prioritizing potential targets for a known drug (called D e here) in a small substructure-drugtarget network. In the initial state (k ¼ 0), scores located in the neighbor nodes of D e were its initial resources. After two resource-spreading processes (k ¼ 2), for each target node T j , the score located in T j was the score of D e -T j interaction. Mathematically, the graph G can be represented by an adjacency matrix A. This is an (N D þ N S þ N T ) order square matrix, defined as:
where M DS is a N D Â N S matrix and M DT is a N D Â N T matrix. They can be respectively defined as:
Let W be an (N D þ N S þ N T ) order square matrix, defined as:
The final resource matrix F can be calculated via following equation:
where W k is the transfer matrix and k is the number of resource-spreading processes. The value of
Predicting targets for new chemical entities
In the substructure-drug (and new chemical entity)-target network, namely aforementioned graph G 0 , new chemical entities can be seen as special drugs that have no known targets. For each new chemical entity C i in this network, its initial resources only located in its substructures. Each substructure equally spreads its resources to neighbor drugs, and then each of those drugs equally spreads its resources to neighbor nodes. Thus, these targets obtained final resources, which can be regarded as the potential targets of C i , where higher score implies higher possibility that C i can act on T j . Such two steps can also be repeated in this way. Figure 1C showed an example of predicting potential targets for a new chemical entity (called C e here) in a small substructure-drug (and new chemical entity)-target network. In the initial state (k ¼ 0), scores located in the neighbor nodes of C e were its initial resources. After two resource-spreading processes (k ¼ 2), for each target node T j , the score located in T j is the score of C e -T j interaction. Mathematically, the adjacency matrix of graph G 0 can be rep-
where M CS is a N C Â N S matrix, defined as:
Let B be an (
order square matrix, defined as:
:
order square matrix, defined as: 
The final resource matrix F' can be computed as below:
where W 0k is the transfer matrix and k is the number of resource-spreading processes. The value of F'(i,
Benchmark evaluation
The performance of SDTNBI was evaluated by 10-fold cross validation, leave-one-out cross validation and external validation.
Ten-fold cross validation
The 10-fold cross validation was widely used in evaluating network-based methods [5, [15] [16] [17] . In a 10-fold cross validation, for the substructure-drug-target network to be evaluated, DTIs were randomly divided into 10 parts. One part was used as the test set in turn. The remnant network, which contained other nine parts and all drug-substructure linkages, was used as the training set. Thus, 10 pairs of training set and test set were obtained. Each pair can be used to calculate a group of evaluation indicators. To reduce randomness of results, the 10-fold cross validation was repeated by 10 times so that 100 groups of evaluation indicators can be used to systematically evaluate the model.
Leave-one-out cross validation
The leave-one-out validation was used to further evaluate the performance of SDTNBI. For the substructure-drug-target network to be evaluated, all DTIs for one drug were extracted to be the test set in turn. The remnant network that contained the DTIs of other drugs and the drug-substructure linkages of this and other drugs was used as the training set. In this way, pairs of training set and test set were generated for the subsequent evaluation indicator calculation. The number of pairs is equal to the number of drugs participated in evaluation.
External validation
The actual generalization ability of predicting potential targets for new chemical entities was also evaluated by several external validation sets. Compounds in the external validation set with known targets were seen as new chemical entities in prediction. After recommended potential targets for those compounds, evaluation indicators were calculated by comparing newly predicted compound-target interactions with known compoundtarget interactions.
Evaluation indicator calculation
For each pair of training set and test set, nodes that lost all its linkages in the training set were removed from both the training set and the test set. After computational DTI prediction on the training set, all possible DTIs were obtained. For each drug D i participating in the evaluation, a sorted list of its newly predicted targets was generated. By comparing these predicted target lists with the test set, several evaluation indicators were calculated to show the accuracy and robustness of the models we built, including precision (P), recall (R), precision enhancement (e P ) and recall enhancement (e R ). The details of these measurements can be found in our previous study [16] , briefly described as below:
where M and N are the number of drugs and targets participated in evaluation (M is always equal to 1 in leave-one-out cross validation), X is the total number of missing DTIs (i.e. DTIs which were divided into test set) of M drugs, X i is the number of missing DTIs of drug D i and X i (L) is the number of true-positive predictions (i.e. missing DTIs which were correctly recovered) ranked in the top L places of the predicted target list of D i . Moreover, for each pair of training set and test set, a receiver operating characteristic (ROC) curve was generated by computing a series of true-positive rates and false-positive rates under different L (L ¼ 1, 2, . . . , N), and a precision-recall curve was also drawn by calculating an array of P(L) and
The areas under these ROC curves were calculated to further show the performance.
Results
Statistics of the benchmark data sets
Five DTI networks and two external validation sets were used in this study ( (Table 1 ). All drugs in the external validation sets were not included in corresponding DTI networks. Meanwhile, seven types of fingerprints were used to systematically describe chemical substructures and were generated for each drug in these data sets. The number of drugs and drugsubstructure linkages are given in Supplementary Table S1 . Substructure-drug (and new chemical entity)-target networks were further constructed for prediction and method validation.
Performance evaluation with cross validation
To evaluate the performance of our models, 10-fold cross validation was carried out under different conditions, including different number of resource-spreading processes (k) and different fingerprints. After 10-fold cross validation was repeated 10 times, for each model, its model performance was evaluated by measuring the averages and standard deviations of several selected evaluation indicators, including area under the receiver operating characteristic curve (AUC), and P, R, e P , e R under selected L. The relationship between AUC values and k values in 10-fold cross validation is given in Supplementary Table S2 . For all network models built via SDTNBI, the AUC value reached its peak when k ¼ 2, and decreased with the increase in k value ( Figure 2 ). The best model performance was independent of different fingerprint types. Hence, 2 was selected as the optimal value of parameter k. Using k ¼ 2, the highest AUC values: 0.966 6 0.002, 0.958 6 0.003, 0.971 6 0.002, 0.932 6 0.005 and 0.949 6 0.004 were yielded for the models of GPCRs-FP4, Kinases-KR, ICs-KR, NRs-KR and Global-FP4, respectively. The details of other evaluation indicators in 10-fold cross validation when k ¼ 2 are given in Table 2 . Moreover, the precision-recall curves in 10-fold cross validation when k ¼ 2 are given in Supplementary Figure S1 . From these evaluation indicators, we found that GPCRs-FP4, Kinases-KR, ICs-KR, NRs-KR and Global-FP4 also showed better performance than other models. To further evaluate the performance of global network models, leave-one-out cross validation was used under different k values and different fingerprints. The relationship between AUC values and k values in leave-one-out cross validation is given in Supplementary Table S3 . We found that the model performance maximized when k ¼ 2, and reduced with the increase in k value. This is consistent with the 10-fold cross validation. Under the optimal condition k ¼ 2, the two highest AUC values of Global were 0.910 6 0.150 and 0.891 6 0.150 for the models of Global-KR and Global-FP4, respectively. The details of other evaluation indicators when k ¼ 2 are shown in Table 3 . We found that KR and FP4 fingerprints outperform other types of fingerprints, which is also consistent with the 10-fold cross validation.
Hence, based on systematic evaluation, the above results suggested that the performance of KR and FP4 fingerprints, especially KR, was better than CDK, CDKExt and Graph fingerprints in SDTNBI. Considering that KR was defined by chemical substructures enriched for bioactivities [25] , the possible explanation is that more specific substructure fragments defined in KR and FP4 could better describe molecules with different bioactivities. In addition, Supplementary Table S1 indicated that the drug-substructure networks with lower sparsity were generated by FP4 or KR. Moreover, the outstanding performance of FP4 or KR also showed in our previous quantitative structureactivity relationship studies [23, 31] . In the future, we will implement and evaluate more types of high-quality fingerprints, such as the Extended Connectivity Fingerprints [32] and threedimensional fingerprints [33] .
Evaluation of the model generalization ability
We further evaluated the model generalization ability of SDTNBI using two external validations sets under different parameter k and different fingerprint types. Consistent with the 10-fold cross validation, for each type of fingerprint, the AUC value reached maximum when k ¼ 2, and decreased with the increase of k value (Supplementary Table S4 ). Using k ¼ 2, the highest AUC values, 0.797 and 0.863, were yielded for the models of GPCRs-KR and Kinases-KR, respectively. In addition to AUC values, these two models also showed the best performance based on other evaluation indicators when k ¼ 2 (Table 4) . For instance, the recall values are 0.573 and 0.657 for the top 20 predictions (L ¼ 20) of GPCRs-KR and Kinases-KR, respectively, suggesting a potential 60% success rate in the future experimental validation. Moreover, from the precision-recall curves (Figure 3) , we found that the performance of KR and FP4 fingerprints was better than other fingerprints for the models of GPCRs, and KR fingerprint slightly outperformed other fingerprints for the models of Kinases. Compared with the precisionrecall curves in the 10-fold cross validation (Supplementary Figure S1) , the curves in external validation did not strictly follow the rule of anticorrelation. The possible reason might be that the number of interactions in the two external validation sets was small (Table 1) . Nevertheless, GPCRs-KR and Kinases-KR further showed high predictive performance on two external validation sets.
Comparison with previous methods
Based on our knowledge, SDTNBI is the first network-based approach that can predict potential targets for new chemical entities on a large scale. Hence, we cannot directly compare the performance of SDTNBI with several previously published methods, such as NBI [15] , DT-Hybrid [17] , NRWRH [18] and CSNAP [34] . In a recent study, Cheng et al. [16] have predicted potential targets for new compounds by integrating the traditional network-based prediction and drug similarity information. The same data sets and external validation sets covering GPCRs and Kinases were used in SDTNBI and the previous study [16] . It is reasonable to compare the performance of SDTNBI with that drug similarity-based method. The drug similarity-based method yielded the highest AUC values, 0.769 and 0.828, for the data sets of GPCRs and Kinases, respectively [16] . Table 4 showed that SDTNBI has the highest AUC values, 0.797 and 0.863, for GPCRs and Kinases, respectively, outperforming the drug similarity-based method.
In addition, we compared SDTNBI with machine learningbased methods. In 2012, Cheng et al. [10] developed two machine learning-based methods, multi-target quantitative structure-activity relationship (mt-QSAR) and computational chemogenomics, for the prediction of chemical-protein interactions. Herein, an external validation set containing 173 interactions connecting 162 compounds and 15 targets were collected from the previous work to assess the generalization ability of our models. Fifteen targets in this data set were included in our DTI network for Kinases. In addition, 162 compounds in this data set were absent in our original DTI network for Kinases. Hence, it is reasonable to compare SDTNBI with the two previously published machine learning-based methods using this external validation set. The evaluation indicators and ROC curves in this external validation set were provided in Supplementary Table S5 and Supplementary Figure S2 , respectively. The AUC values from 0.922 to 0.927 were yielded for the models of Kinases built via SDTNBI across seven different types of fingerprints (Supplementary Table S5 ), outperforming the AUC values, 0.865 and 0.604, for the models of kinases built via mt-QSAR and computational chemogenomics [10] . Collectively, aforementioned analyses suggested that SDTNBI outperformed the previously developed drug similarity-based method [16] and two machine learning-based methods (i.e. mt-QSAR and computational chemogenomics) [10] .
Case studies: discovery of potential anticancer targets for NSAIDs
NSAIDs are a big class of drugs that can be used for antipyretic, analgesic and anti-inflammatory effects. Recently, NSAIDs have shown potential anticancer indications [35] . However, the exact molecular mechanisms of antitumor effects of NSAIDs were still unknown. Herein, to illustrate the practical applications of SDTNBI, we investigated the potential molecular mechanisms of the antitumor effects of NSAIDs, by integrating the known and newly predicted DTIs for NSAIDs via SDTNBI and related gene-disease associations.
In this study, NSAIDs were collected from our previous study [36] . Then, potential new targets ranked in the top five with the highest predicted scores were yielded for each NSAID by using the global model Global-FP4 (k ¼ 2), which showed the best performance in the 10-fold cross validation. The gene symbols of all known and predicted targets were extracted from the UniProt database [37] . The corresponding gene-disease associations were downloaded from the Comparative Toxicogenomics Database [38] , and only those curated items covering cancer were retained. The cancers from those gene-cancer associations were subsequently filtered and merged by referring to the MeSH (http://www.nlm.nih.gov/mesh/) tree structure categories. Finally, 211 DTIs connecting 21 NSAIDs and 55 targets, and 100 gene-disease associations connecting 28 genes and 29 cancers were obtained ( Figure 4) . A drug-gene-disease subnetwork for these NSAIDs was then constructed using the CytoScape software (version 3.1.1) [39] . Note. FP ¼ the fingerprint type used in generating drug-substructure linkages; P ¼ precision; R ¼ recall; e P 5 precision enhancement; e R ¼ recall enhancement.
As shown in Figure 4 , cyclooxygenase-2 (COX-2) encoded by PTGS2, a well-known primary target for NSAIDs, has high degree in the drug-gene-disease network. Previous studies have suggested that COX-2 plays crucial roles in cancer [40] , such as colorectal cancer [41] [42] [43] , pancreatic cancer [44] and breast cancer [45] . In addition, inhibition of COX-2 by NSAIDs has potential anticancer indications for colorectal cancer [46] and breast cancer [47] . In this study, we chose several other potential targets that are less reported to have new anticancer indications to explore new potential mechanisms of the anticancer indications for NSAIDs via SDTNBI and network analyses. For instance, AKR1C3, a member of aldo/ketoreductase superfamily, was predicted as a novel potential antitumor target for several NSAIDs. Several previous studies reported that AKR1C3 plays crucial roles in various diseases, including prostate cancer [48] [49] [50] . Previous preclinical studies demonstrated that multiple NSAIDs, such as Diclofenac [51] , Flurbiprofen [52] , Ibuprofen [53] , Indomethacin [54] and Meclofenamic acid [55] , have the potential antiprostate cancer indications. Moreover, NSAIDs have been well characterized as potent AKR1C3 inhibitors based on previously pharmacological experiments [56, 57] and co-crystal structure data [58, 59] . Thus, the predicted interactions such as Diclofenac-AKR1C3 and Ibuprofen-AKR1C3 via SDTNBI were consistent with published evidence. We also found that carbonic anhydrases are potential anticancer targets for several NSAIDs. Several carbonic anhydrase isoforms, including CA9 [60, 61] and CA12 [62, 63] , are associated with breast cancer. Previous studies have reported that NSAIDs, including Acetaminophen [64] and Celecoxib [47] , have potential antibreast cancer effects. Biological assays have showed that NSAIDs, including Acetaminophen, Celecoxib and Valdecoxib, are potent CA9 or CA12 inhibitors [65] [66] [67] . Collectively, inhibiting AKR1C3, CA9 or CA12 by NSAIDs may provide new strategy for cancer chemoprevention.
In addition, we also computationally identified new potential anticancer indications for several NSAIDs, such as Carprofen, Etodolac and Rofecoxib, via SDTNBI. Specifically, we computationally identified that CDK2 may be targeted by Carprofen, Etodolac and Rofecoxib (Figure 4) . Previous studies demonstrated that CDK2 plays crucial roles mediating tumorigenesis and tumor progression in several cancer types [68] , such as melanoma [69] and prostate cancer [70] . For example, a recent study showed that Carprofen induces cell apoptosis by targeting the p38 MAPK pathway in prostate cancer cells [71] . Cheng et al. [72] found that Etodolac inhibited CDK2, CDK4 and CDC2 expression and further repressed tumor growth in human hepatocellular carcinoma cell lines. Tanaka et al. [73] found that oral doses of Rofecoxib showed a potential value for the treatment of non-small cell lung cancer. In summary, the potential anticancer indications for Carprofen, Etodolac and Rofecoxib predicted via SDTNBI are consistent with the previous literature evidences. Further study will be needed to provide experimental validations, which we hope will be prompted by the findings herein. Finally, all newly predicted targets ranked in the top 20 for 1844 drugs via the aforementioned best global model are available on request for experimental investigation in the future.
Tool development
We developed a toolkit called NetInfer via C þþ for predicting new potential targets for known drugs, failed drugs and new chemical entities on a large scale. Both SDTNBI and previously developed NBI were implemented in this toolkit. NetInfer is light weight and does not need the support of any third-party math libraries such as linear algebra libraries. To accelerate the calculation and decrease the cost of memory space, different data structures were designed for the sparse and dense matrices. It provides functions of prediction, cross validation and external validation. In a uniform platform, researchers can input their in-house data into our toolkit and then obtain predictive lists or evaluation indicators.
Input file format
To input their own data into NetInfer for DTI prediction, users should convert the data into a specific format. Each network stores in a text file, which contains numerous lines representing edges in the network and five columns separated by 'Tab' character. For a edge between node A and node B, the five columns denote (i) the type of node A, (ii) the identifier of node A, (iii) the type of node B, (iv) the identifier of node B and (v) the weighted value of edge A-B, respectively. Currently, NetInfer only supports unweighted networks so that the weighted values are always '1'.
To prioritize targets for known drugs, users have to prepare an input file of known DTI network. For example, the raw data can be downloaded from relative databases such as DrugBank [27] , BindingDB [28] and ChEMBL [26] . Subsequently, users convert the data into cleaned DTI pairs without duplicates, and then save them into a text file with aforementioned format. The detailed protocols are provided in Figure 5 . Each line represents a DTI in this text file, where five columns denote (i) the type of drug node, (ii) the drug identifier, (iii) the type of target node, (iv) the target identifier and (v) the weighted value of edge. We recommended users to use two simple strings 'DRUG' and 'TARGET' as the type of drug node and target node, respectively. In current version, NetInfer supports different types of drug identifiers. For example, the drug identifiers can be predefined by existing databases, such as DrugBank ID, ChEMBL ID and PubChem Compound ID, or defined by users. In this study, to avoid the duplicates of drug molecules from different data sources, we used a unique in-house hash code generated from canonical SMILES via a hashing algorithm as the drug identifier. Similarly, different types of target identifiers, such as UniProt accession numbers or gene symbols, are supported by NetInfer. For instance, as shown in Figure 5A , the first line means that there is a drug 'D-0001' that can act on a target 'P00374' in a DTI network, and the lines from 2 to 7 means that the drug 'D-0002' has known interactions with six targets, including 'P08254', 'P09237', etc. In addition to a known DTI network, an input file of known drug-substructure network should also be prepared. As shown in Figure 5B , each line represents a drug-substructure linkage in this text file, where five columns denote (i) the type of drug node (e.g. 'DRUG'), (ii) the drug identifier, (iii) the type of substructure node (e.g. 'SUB'), (iv) the substructure identifier and (v) the weighted value of edge. We recommended users to use 'DRUG' and 'SUB' as the type of drug node and substructure node, respectively. The string used as the type of drug node as well as drug identifiers should be consistent with the former input file. SDTNBI in NetInfer will use these two input files to construct a substructure-drug-target network ( Figure 1A) , and then predict potential targets for known drugs. and substructure node, respectively. The string used as the type of substructure node should be consistent with the prepared input file of drug-substructure network. Moreover, the fingerprint type for generating new chemical entity-substructure network must be same as which was used in drug-substructure network. For instance, as shown in Figure 5C , the input file shows that the new chemical entity 'C-0001' harbors several substructures, such as 'MACCSFP16', 'MACCSFP22', etc.
The input file of the new chemical entity-substructure network can be prepared as following steps. First, two columns separated by 'Tab' character, respectively, containing the SMILES strings and identifiers of new chemical entities to be predicted, are saved in a SMILES file. Subsequently, users can generate substructures for these molecules with their selected fingerprints. For instance, this SMILES file can be converted into a comma separated value (CSV) format file with compoundsubstructure information by the PaDEL-Descriptor software [30] . And then, an in-house Python script can be used to convert the CSV file into a text file that can be inputted into NetInfer. An example describes as below:
where 'INPUT.csv' is the CSV format file to be converted, and 'OUTPUT.txt' is the text file to be generated. Users can replace the filename according to practical situation. It is noteworthy that this script can also be used to prepare the aforementioned input file of drug-substructure network if replacing the 'COMPOUND' by 'DRUG'. Finally, SDTNBI in NetInfer will use three input files, namely this input file of new chemical entitysubstructure network and aforementioned two input files of known DTIs and drug-substructure network, to construct a substructure-drug (and new chemical entity)-target network ( Figure 1A) , and then predict potential targets for new chemical entities.
Target prediction via SDTNBI After preparing input files, users can execute SDTNBI in NetInfer to prioritize potential targets for known drugs, failed drugs or new chemical entities via command line. In the command line, the number of resource-spreading processes (k) and the number of targets to be predicted for each drug or compound are given by users. Furthermore, according to actual projects, users can provide two input files for prioritizing targets for known drugs, or three input files for predicting targets for failed drugs or new chemical entities. The detailed command lines for prediction, cross validation and external validation were all presented at our Web site (http://lmmd.ecust.edu.cn/methods/ sdtnbi/).
Output file format
The predicted results of NetInfer are saved in a text file. Each line also represents a DTI in this output file, where six columns separated by 'Tab' character denote (i) the type of node A, (ii) the identifier of node A, (iii) the type of node B, (iv) the identifier of node B, (v) the score of A-B and (vi) the ranking position of B at the sorted list of all predicted objects of A. It is noteworthy for j in range(1, len(x)):
that known DTIs will also be outputted into this file if they exist, whereas their ranking position will be represented as character '-', instead of an integer number. For instance, as shown in Figure 5D , the known drug 'D-0001' with a known interaction with 'P00364' was predicted to have potential targets 'Q12809', 'P28335', etc. Similarly, as shown in Figure 5E , the new chemical entity 'C-0002' without known targets was predicted to have potential targets 'P24941', 'P00918', etc. Users can use these known and predicted DTIs to build networks for analysis, or choose newly predicted interactions with high scores for further experimental validation.
Discussion
In this study, we developed a novel integrated network and chemoinformatics tool, named SDTNBI, to predict potential targets not only for old drugs but also for failed drugs and new chemical entities on a large scale. Although several existing network-based prediction methods such as NBI [15] , EWNBI and NWNBI [16] have achieved high accuracy and robustness in DTI prediction, they could not prioritize potential targets for new chemical entities without known targets in DTI network, such as newly synthesized structures and failed drugs in phases II and III. To overcome this defect, SDTNBI imports chemical substructures to link those new chemical entities with known DTI network. It can predict hundreds of potential targets for thousands of drugs or new chemical entities at the same time by systematically searching a global substructuredrug-target tripartite network. Based on systematic evaluation, we found that SDTNBI has the best performance when the number of resource-spreading processes (k) is 2, and the performance decreased with the increasing of k. The possible reason of this phenomenon might be that the resources will be located more dispersedly in the network as the increasing of k. This dispersion might lead to worse method performance. Meanwhile, seven commonly used fingerprints, which are all freely available, were systematically tested. Under the optimal condition, SDTNBI yields high performance in the 10-fold cross validation, leave-one-out cross validation and external validation. Furthermore, we developed a useful toolkit and predicted thousands of new potential DTIs for Food and Drug Administration-approved or clinical investigational drugs, which are available for future validation for academic users such as experimental scientists. For example, case studies for identifying anticancer mechanisms of action of NSAIDs have shown practical applications of SDTNBI. Hence, SDTNBI would provide a highly efficient and low-cost tool for DTI prediction and drug repositioning in drug discovery.
There are several significant contributions and advantages of SDTNBI compared with previously published methods, such as network-based methods [15, 16] , machine learning-based methods [10] [11] [12] and molecular docking [8, 9, 36] . First, the most key contribution of SDTNBI is that it can be used to predict potential targets for new chemical entities, whereas traditional network-based methods cannot. Machine learning-based methods and models with high accuracy have been developed for predicting targets to new chemical entities. For example, Yamanishi et al. [11] built bipartite graph learning models by integrating chemical protein sequence similarity information, and then further built the supervised bipartite graph learning model by integrating chemical similarity, protein sequence similarity information and pharmacological data [12] . However, traditional machine learning-based models have several potential pitfalls. In generally, most machine learning-based models are built via constructing positive against negative samples. High quality and large-scale diverse molecules with wide target coverage and gold negative data sets are crucial for machine learning-based model development [7] . However, it is always difficult to construct a negative data set with enough size and gold standard because there are few experimentally validated inactive data published in literatures. Most negative data sets in the machine learning-based models are randomly constructed based on the principle of 'one-versus-the-rest', such as our previously developed mt-QSAR and computational chemogenomics methods [10] , resulting in negative samples much more than positive samples. The accuracy of models was often reduced with these low-quality negative samples, even though they might be selected to keep the balance between positive and negative samples. In this study, SDTNBI inherited the advantages of both network-based and chemoinformatics-based approaches. It builds network models based on only positive DTIs to predict potential targets for both known drugs and new chemical entities on a large scale. As described in the method comparison, SDTNBI outperformed the previously developed drug similarity-based method [16] , mt-QSAR and computational chemogenomics methods [10] . Moreover, like other network-based methods, SDTNBI does not rely on threedimensional structures of protein targets and small molecules. Hence, it can predict more varieties of targets for usergiven molecules compared with molecular docking approaches, such as TarFisDock [8] and DRAR-CPI [9] . Finally, SDTNBI can also be used in other networks, such as drug-disease network [6] , drug-side effect network [74] , drug-microRNA network [5] and drug-single-nucleotide polymorphisms network by systematically incorporating multiple-scale biomedical data, such as drug-gene signatures from LINCSCLOUD (http://www.linc scloud.org), structured data generated from electronic health records [75] and drug pharmacogenomics data from PharmGKB [76] .
However, there are still several possible limitations of SDTNBI. First, it cannot predict potential DTIs for targets absent in the existing DTI network because of no reachable paths among those targets and the known network. Second, if there is a molecule with a special chemical structure, which shared none or only a few substructures with known drugs in the DTI network, SDTNBI cannot accurately predict targets for it. Third, for each drug in the substructure-drug-target tripartite network, it has two types of neighbor nodes standing for substructures and targets, respectively. But we did not differentiate them in resource-spreading processes. Equal amount of initial resources was allocated to each of its neighbor nodes, no matter it being a substructure or a target. Meanwhile, equal weighted values were set for each of its edges, no matter it being a drug-substructure linkage or a DTI. This equal treatment might cause potential unbalances and then decrease the performance of SDTNBI. Moreover, the influence of hub nodes was not investigated yet. We are actively developing improved methods to solve these potential limitations, such as node-weighted or edge-weighted network-based approaches. Nevertheless, SDTNBI would provide powerful tools for DTI prediction and drug repositioning for drug discovery and personalized medicine in the future. 
